STAT+: The latest orphan drug exemptions may not be warranted, analysis finds

A new analysis questions the justification for expanded exemptions of orphan drugs from Medicare pricing negotiations under the Orphan Cures Act, which broadened protections for drugs with multiple rare disease indications. The law delays price negotiation timelines for these drugs, despite concerns they may not warrant such exemptions.